Nonalcoholic fatty liver disease and cardiovascular risk.
about
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval PathwayComposite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countriesSirtuins and nonalcoholic fatty liver diseaseNon-Alcoholic Fatty Liver Disease Association with Cardiac ArrhythmiasIndependent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis.Nonalcoholic Steatohepatitis: A Search for Factual Animal Models.Metabolic syndrome and hepatic resection: improving outcomeAssociation of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysisDyslipidemia in patients with nonalcoholic fatty liver disease.The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults.Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseaseSteatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD.Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistanceChronic hepatitis B, nonalcoholic steatohepatitis and physical fitness of military males: CHIEF study.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.Frequency of Nonalcoholic Fatty Liver Disease and Subclinical Atherosclerosis Among Young Mexican Americans.Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease.Correlation between severity of ultrasonographic nonalcoholic fatty liver disease and cardiometabolic risk among Filipino wellness patientsCombination drug treatment in patients with non-alcoholic fatty liver disease.Fatty liver without a large "belly": Magnified review of non-alcoholic fatty liver disease in non-obese patients.Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure.Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study.Quantification of fetal organ volume and fat deposition following in utero exposure to maternal Western Diet using MRI.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.Regulation of Mitochondrial Trifunctional Protein Modulates Nonalcoholic Fatty Liver Disease in Mice.Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease.Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic.Association between Nonalcoholic Fatty Liver Disease and Carotid Artery Disease in a Community-Based Chinese Population: A Cross-Sectional Study
P2860
Q26800894-4956E765-D368-421B-8890-0FA9EEB2CB69Q26828855-0DE40026-8A7C-4C51-BDBA-31EB36633BBBQ28079953-769A9F47-3AAF-4463-B743-A8FFB441C170Q33675914-FD63B476-943F-483D-A60A-05C5B0F64947Q34729697-FBA5FA31-6229-4A66-87D6-1312B33E41FAQ35612535-221158C6-6525-4CB4-BA01-5896F5579186Q35629684-77EA671E-188F-47CF-A230-FC8BDBB9E45FQ36134867-60182B6E-4D0F-43A9-A791-73FF88DBC0B3Q36845703-D3E45611-A58B-49D5-B4B5-00586F827517Q36983522-3A92E030-E624-41B2-9D47-7C20EEF76149Q37196514-B5618E8B-3844-429D-BA35-F8C49F6AAB00Q37206782-BF670E35-F5C9-43F2-9B23-F2A8A217CC0AQ37652049-7D2763FF-B8A0-4528-BEC6-F96B829241C3Q38652393-82D738B0-F6AF-4322-866E-2295B8C059C7Q38674742-0457C53A-B449-404B-9243-3420E265E068Q39363389-1724D6B8-D564-4B96-A6C7-6E1331C0767AQ39445103-3C64295E-471A-4F0B-9458-C99D8A9D3481Q40249563-535917D4-AE4A-4804-B7C1-4EBCD5BE8666Q40958800-102A1FCA-87BF-48D0-95B7-C69FA0799148Q41051779-4FC76DC8-C20B-484A-9159-6E8809A87632Q41128646-977C7B3B-E406-408E-A9C5-55D11A7F35E4Q41449920-6D99000D-C89A-4632-BDA9-A4D4E6873838Q43582639-12DBD028-5C74-477C-9E0E-C9A977E54DECQ47380867-535A4334-97AC-40E8-BF71-5239745BD41DQ47890127-6014FC75-85FC-467A-A6DF-7DE0F4EE17AAQ47969190-8F18CA88-62ED-4CB1-9DB7-0575A9ACF92AQ49980187-EE40116C-BF8B-4198-8C82-759C8A93EF25Q50136712-6B5341AE-9EBA-4D62-B35D-7943D555F40EQ51759255-4E580478-B766-4C28-8174-63054BD5DCCBQ53644437-E6C65217-A619-40C4-9D11-A2D809F2B3D3Q55074201-64B3BB21-1CC1-4ADB-8A6A-FB81EC17DC31Q56979475-513BBCAA-15F7-4075-88E8-7F30061C0292
P2860
Nonalcoholic fatty liver disease and cardiovascular risk.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nonalcoholic fatty liver disease and cardiovascular risk.
@en
Nonalcoholic fatty liver disease and cardiovascular risk.
@nl
type
label
Nonalcoholic fatty liver disease and cardiovascular risk.
@en
Nonalcoholic fatty liver disease and cardiovascular risk.
@nl
prefLabel
Nonalcoholic fatty liver disease and cardiovascular risk.
@en
Nonalcoholic fatty liver disease and cardiovascular risk.
@nl
P2860
P1476
Nonalcoholic fatty liver disease and cardiovascular risk.
@en
P2093
Naga Chalasani
Vijay Laxmi Misra
P2860
P2888
P356
10.1007/S11894-009-0008-4
P577
2009-02-01T00:00:00Z